12/2
08:00 am
ewtx
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Medium
Report
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
11/22
02:11 am
ewtx
Edgewise Therapeutics (NASDAQ:EWTX) was upgraded by analysts at
Wall Str
Medium
Report
Edgewise Therapeutics (NASDAQ:EWTX) was upgraded by analysts at
Wall Str
11/20
08:22 am
ewtx
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors [Yahoo! Finance]
Low
Report
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors [Yahoo! Finance]
11/20
08:00 am
ewtx
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors
Low
Report
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors
11/18
12:42 pm
ewtx
Will Edgewise Therapeutics' (EWTX) New CFO Mark a Shift in Its Commercial Strategy? [Yahoo! Finance]
Low
Report
Will Edgewise Therapeutics' (EWTX) New CFO Mark a Shift in Its Commercial Strategy? [Yahoo! Finance]
11/16
10:26 pm
ewtx
Edgewise Therapeutics (EWTX) Reports Heightened R&D Activity in Q3 2025 [Yahoo! Finance]
Low
Report
Edgewise Therapeutics (EWTX) Reports Heightened R&D Activity in Q3 2025 [Yahoo! Finance]
11/14
10:56 am
ewtx
Edgewise Therapeutics (NASDAQ:EWTX) had its price target raised by analysts at JPMorgan Chase & Co. from $33.00 to $34.00. They now have an "overweight" rating on the stock.
Low
Report
Edgewise Therapeutics (NASDAQ:EWTX) had its price target raised by analysts at JPMorgan Chase & Co. from $33.00 to $34.00. They now have an "overweight" rating on the stock.
11/12
08:00 am
ewtx
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Medium
Report
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
11/10
08:38 am
ewtx
Edgewise Therapeutics announces appointment of Michael Nofi as CFO [Seeking Alpha]
Medium
Report
Edgewise Therapeutics announces appointment of Michael Nofi as CFO [Seeking Alpha]
11/10
08:18 am
ewtx
Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers [Yahoo! Finance]
Medium
Report
Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers [Yahoo! Finance]
11/10
08:00 am
ewtx
Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers
Medium
Report
Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers
11/9
03:42 pm
ewtx
Edgewise Therapeutics (EWTX): Assessing Valuation Following Recent Share Price Volatility [Yahoo! Finance]
Medium
Report
Edgewise Therapeutics (EWTX): Assessing Valuation Following Recent Share Price Volatility [Yahoo! Finance]
11/7
02:22 pm
ewtx
Edgewise Therapeutics (NASDAQ:EWTX) had its price target raised by analysts at Royal Bank Of Canada from $49.00 to $50.00. They now have an "outperform" rating on the stock.
Low
Report
Edgewise Therapeutics (NASDAQ:EWTX) had its price target raised by analysts at Royal Bank Of Canada from $49.00 to $50.00. They now have an "outperform" rating on the stock.
11/7
10:27 am
ewtx
Edgewise Therapeutics (NASDAQ:EWTX) had its price target lowered by analysts at Wedbush from $35.00 to $32.00. They now have an "outperform" rating on the stock.
Low
Report
Edgewise Therapeutics (NASDAQ:EWTX) had its price target lowered by analysts at Wedbush from $35.00 to $32.00. They now have an "outperform" rating on the stock.
11/7
08:00 am
ewtx
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
11/6
08:00 am
ewtx
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Medium
Report
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
11/3
08:00 am
ewtx
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Medium
Report
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
10/24
12:21 pm
ewtx
Edgewise Therapeutics (NASDAQ:EWTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Edgewise Therapeutics (NASDAQ:EWTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/9
07:29 am
ewtx
How Investors May Respond To Edgewise Therapeutics (EWTX) Long-Term Sevasemten Data at World Muscle Congress [Yahoo! Finance]
Low
Report
How Investors May Respond To Edgewise Therapeutics (EWTX) Long-Term Sevasemten Data at World Muscle Congress [Yahoo! Finance]
10/8
12:20 pm
ewtx
Edgewise Therapeutics (NASDAQ:EWTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Edgewise Therapeutics (NASDAQ:EWTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/2
04:13 pm
ewtx
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules [Yahoo! Finance]
Medium
Report
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules [Yahoo! Finance]
10/2
04:01 pm
ewtx
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Medium
Report
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
10/2
08:00 am
ewtx
Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society
Medium
Report
Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society
9/26
06:54 am
ewtx
Edgewise Therapeutics (NASDAQ:EWTX) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "hold" rating.
Medium
Report
Edgewise Therapeutics (NASDAQ:EWTX) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "hold" rating.
9/25
08:06 am
ewtx
Edgewise Therapeutics (NASDAQ:EWTX) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $20.00 price target on the stock.
High
Report
Edgewise Therapeutics (NASDAQ:EWTX) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $20.00 price target on the stock.